ArticlePloS one2026
IL5 rs2069812 and IL13 rs1800925 Genetic variants as key determinants of clinically relevant asthma phenotypes.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2-high airway inflammation in adults with asthma is heavily driven by the cytokines interleukin (IL)-4, IL-5, and IL-13. While genetic variations in these cytokines are known to influence asthma pathogenesis, their specific impacts on clinically relevant phenotypes remain to be fully elucidated. This study aimed to investigate the associations between inflammatory cytokine gene polymorphisms, clinical asthma phenotypes, inflammation cell subtypes, and lung function. A cross-sectional study was conducted involving 125 adults with asthma. Genotyping was performed for the following single-nucleotide polymorphisms (SNPs): IL33 (rs1342326, rs3939286), IL4 (rs2243250, rs2243248), IL5 rs2069812, and IL13 (rs20541, rs1800925). Clinical evaluations included lung function, blood eosinophils, type 2 innate lymphoid cells (ILC2s), Th2 cells, cytokine levels, and specific IgE. The IL4 rs2243248 TT genotype was associated with higher TNF-α (p = 0.038), while the IL13 rs1800925 polymorphism was associated with increased Th2 cell counts (p = 0.025). Notably, IL5 rs2069812 was strongly associated with blood eosinophilia (p < 0.001) and reduced lung function. Linear regression revealed a significant gene-dose effect of IL-5 rs2069812 T allele, which correlated with an increase in log10 eosinophils (β = 0.207, p < 0.001) and a decrease in post-bronchodilator FEV1% (β = -7.38, p = 0.014). Furthermore, the IL5 rs2069812 and IL13 rs1800925 variants significantly increased the risk of blood eosinophilia (Prevalence Ratio [PR] = 2.59, p < 0.001) and fixed airflow obstruction (PR = 1.81, p = 0.039), respectively. The IL5 rs2069812 and IL13 rs1800925 polymorphisms serve as key genetic determinants of persistent blood eosinophilia and fixed airflow obstruction, respectively. Both variants significantly contribute to the severity of airflow limitation in adult asthma, highlighting their potential as biomarkers for precision phenotyping.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.